The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study.

Ewa JanczewskaDorota Zarębska-MichalukHanna BerakAnna PiekarskaAndrzej GietkaDorota DybowskaWłodzimierz MazurTeresa Belica-WdowikWitold DobrackiMagdalena Tudrujek-ZdunekZbigniew DerońIwona BuczyńskaMarek SitkoAgnieszka Czauż-AndrzejukBeata LorencJolanta Białkowska-WarzechaJolanta CitkoŁukasz LauransJerzy JaroszewiczŁukasz SochaOlga TroninaBrygida AdamekAndrzej HorbanWaldemar HalotaBarbara Baka-ĆwierzKrzysztof TomasiewiczKrzysztof SimonAleksander GarlickiMarta Wawrzynowicz-SyczewskaRobert Flisiak

Published in: BMC infectious diseases (2018)

Efficacy and safety of treatment with PrODR and LSR is comparable in BOC or TVR-experienced patients.

Keyphrases

hepatitis c virus
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
clinical trial
cross sectional
replacement therapy